Unknown

Dataset Information

0

Impact of Endoscopic Ultrasound-Guided Tissue Acquisition on Decision-Making in Precision Medicine for Pancreatic Cancer: Beyond Diagnosis.


ABSTRACT: Precision medicine in cancer treatment refers to targeted therapy based on the evaluation of biomarkers. Although precision medicine for pancreatic cancer (PC) remains challenging, novel biomarker-based therapies, such as pembrolizumab, olaparib, and entrectinib, have been emerging. Most commonly, endoscopic ultrasound-guided tissue acquisition (EUS-TA) had been used for the diagnosis of PC until now. However, advances in EUS-TA devices and biomarker testing, especially next-generation sequencing, have opened up the possibility of sequencing of various genes even in limited amounts of tissue samples obtained by EUS-TA, and identifying potential genetic alterations as therapeutic targets. Precision medicine benefits only a small population of patients with PC, but biomarker-based therapy has shown promising results in patients who once had no treatment options. Now, the role of EUS-TA has extended beyond diagnosis into decision-making regarding the treatment of PC. In this review, we mainly discuss tissue sampling by EUS-TA for biomarker testing and the current status of precision medicine for PC.

SUBMITTER: Imaoka H 

PROVIDER: S-EPMC8307595 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4115182 | biostudies-literature
| S-EPMC10571848 | biostudies-literature
| S-EPMC8502022 | biostudies-literature
| S-EPMC8703478 | biostudies-literature
| S-EPMC8283288 | biostudies-literature
| S-EPMC10611524 | biostudies-literature
| S-EPMC4858215 | biostudies-literature
| S-EPMC8828213 | biostudies-literature
| S-EPMC6302202 | biostudies-other